Renova, Janssen team up to develop stresscopin

Renova Therapeutics Inc. recently entered an alliance with Janssen Pharmaceuticals Inc. for the development of new treatments for congestive heart failure and Type 2 diabetes.
The new gene therapy treatment that is being formulated would help target the many issues caused by congestive heart failure, as well as Type 2 diabetes, through the use of an investigational new drug filre, also known as stresscopin. 
"Obtaining this stresscopin program IND helps propel forward the development of our peptide infusion product candidate, RT-400," Renova Therapeutics CEO and co-founder Jack Reich said. "With this data, we hope to see promising results as we initiate pivotal trials."
Stresscopin is a hormone that is used for physiological stress. The treatment of heart failure conditions is important, as in the U.S. alone, Acute Decompensated Heart Failure (ADHF) makes up about half of all heart failure-related instances of hospitalization. 
In this agreement, stresscopin, which was being developed by Janssen, will be transferred to Renova, where the biotechnology company will seek to advance it as RT-400, which is a peptide infusion treatment for ADHF.